Literature DB >> 12405485

Update of ocular manifestations in sarcoidosis.

Yoshihiko Usui1, Elizabeth D E Kaiser, Robert F See, Narsing A Rao, Om P Sharma.   

Abstract

Although the lung is the primary target of involvement, sarcoidosis can involve any organ in the body, including the eye. Ocular involvement may also be the initial manifestation of sarcoidosis in many patients. Since no characteristic clinical feature heralds the onset of ocular involvement in sarcoidosis, a systematic eye examination is advised. This review discusses ocular manifestations and changes based upon the anatomic site of the eye, ocular tissue biopsy, and treatment. Early recognition and intervention are essential for the reduction of ocular morbidity and the improvement of the patient's quality of life.

Entities:  

Mesh:

Year:  2002        PMID: 12405485

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  5 in total

Review 1.  Practical issues and challenges in the diagnosis and treatment of pulmonary sarcoidosis.

Authors:  Surinder K Jindal
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  A patient with sarcoidosis diagnosed by a biopsy of scleral nodules.

Authors:  Wataru Saito; Satoshi Kotake; Shigeaki Ohno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-10-13       Impact factor: 3.117

3.  Neurosarcoidosis--a diagnostic pitfall with consequences.

Authors:  Irene Kapfhammer; Christine Armbruster; Christian Armbruster
Journal:  Wien Klin Wochenschr       Date:  2006-09       Impact factor: 1.704

4.  Association of complement factor H tyrosine 402 histidine genotype with posterior involvement in sarcoid-related uveitis.

Authors:  Ian A Thompson; Baoying Liu; H Nida Sen; Xiadong Jiao; Robert Katamay; Zhiyu Li; Mengjun Hu; Fielding Hejtmancik; Robert B Nussenblatt
Journal:  Am J Ophthalmol       Date:  2013-03-14       Impact factor: 5.258

5.  Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis.

Authors:  José Luis Callejas-Rubio; Lourdes López-Pérez; Norberto Ortego-Centeno
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.